Burden of Disease Among Exacerbating Patients with COPD Treated with Triple Therapy in Spain

References

• Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2020 Report). Available from: https://goldcopd.org/gold-reports/. Accessed April 1, 2019.
   Google Scholar
• Soriano JB, Alfageme I, Miravitlles M, et al. Prevalence and determinants of COPD in Spain: EPISCAN II. Arch Bronconeumol. 2021;57(1):61–69.
   PubMed Web of Science ®Google Scholar
• Masa JF, Sobradillo V, Villasante C, et al. Costs of chronic obstructive pulmonary disease in Spain. Estimation from a population-based study. Arch Bronconeumol. 2004;40(2):72–79.
   PubMed Web of Science ®Google Scholar
• Merino M, Villoro R, Hidalgo-Vega Á, Carmona C. Social economic costs of COPD in Extremadura (Spain): an observational study. Int J Chron Obstruct Pulmon Dis. 2018;Volume 13:2501–2514.
   Web of Science ®Google Scholar
• Pérez M, Puig-Peiró R, Paz S, Lizán L. Coste directo de la enfermedad pulmonar obstructiva crónica asociado a variaciones en adherencia y persistencia. Rev Patol Respir. 2015;18(2):49–56.
   Google Scholar
• Miravitlles M, Ribera A. Understanding the impact of symptoms on the burden of COPD. Respir Res. 2017;18(1):67.
   PubMedGoogle Scholar
• Calle Rubio M, Rodríguez Hermosa JL, Soler-Cataluña JJ, et al. Medical Care According To Risk Level And Adaptation to Spanish COPD Guidelines (Gesepoc): the Epoconsul study. Arch Bronconeumol. 2018;54(5):270–279.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Morgan RL, Alonso-Coello P, et al. A systematic review of how patients value COPD outcomes. Eur Respir J. 2018;52(1):1.
   Web of Science ®Google Scholar
• Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med. 2015;3(6):435–442.
   PubMed Web of Science ®Google Scholar
• Siddiqui SH, Guasconi A, Vestbo J, et al. Blood eosinophils: a biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;192(4):523–525. 10.1164/rccm.201502-0235LE
   PubMed Web of Science ®Google Scholar
• Bafadhel M, McCormick M, Saha S, et al. Profiling of sputum inflammatory mediators in asthma and chronic obstructive pulmonary disease. Respiration. 2012;83(1):36–44. 10.1159/000330667
   PubMed Web of Science ®Google Scholar
• Bafadhel M, Davies L, Calverley PMA, Aaron SD, Brightling CE, Pavord ID. Blood eosinophil guided prednisolone therapy for exacerbations of COPD: a further analysis. Eur Respir J. 2014;44(3):789–791.
   PubMed Web of Science ®Google Scholar
• Vedel-Krogh S, Nielsen SF, Lange P, Vestbo J, Nordestgaard BG. Blood eosinophils and exacerbations in Chronic Obstructive Pulmonary Disease. The copenhagen general population study. Am J Respir Crit Care Med. 2016;193(9):965–974.
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Monteagudo M, Solntseva I, Alcázar B. Blood eosinophil counts and their variability and risk of exacerbations in COPD: a population-based study. Arch Bronconeumol. 2021;57(1):13–20.
   PubMed Web of Science ®Google Scholar
• Golpe R, Dacal D, Sanjuán-López P, Martín-Robles I, Pérez-de-llano LA. Plasma eosinophil count and patient-centered events in chronic obstructive pulmonary disease in real-life clinical practice. Arch Bronconeumol. 2020;56(2):129–130.
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Murio C, Guerrero T, Gisbert R. Costs of chronic bronchitis and COPD: a 1-year follow-up study. Chest. 2003;123(3):784–791.
   PubMed Web of Science ®Google Scholar
• de Miguel Diez J, Carrasco Garrido P, García Carballo M, et al. Determinants and predictors of the cost of COPD in primary care: a Spanish perspective. Int J Chron Obstruct Pulmon Dis. 2008;3(4):701–712.
   PubMedGoogle Scholar
• International Conference of Harmonization (ICH). ICH Tripartite Guideline for Good Clinical Practices E6 (R1).
   Google Scholar
• International Epidemiological Association-European Epidemiology Federation. Good epidemiological practice (GEP) IEA guidelines for proper conduct in epidemiologic research. 2007. Available from: http://ieaweb.org/good-epidemiological-practice-gep/.
   Google Scholar
• Rieger-Reyes C, García-Tirado FJ, Rubio-Galán FJ, Marín-Trigo JM. Clasificación de la gravedad de la enfermedad pulmonar obstructiva crónica según la nueva guía Iniciativa Global para la Enfermedad Obstructiva Crónica 2011: COPD Assessment Test versus modified Medical Research Council. Arch Bronconeumol. 2014;50(4):129–134.
   PubMedGoogle Scholar
• Jones PW, Harding G, Berry P, Wiklund I, Chen W-H, Kline Leidy N. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009;34(3):648–654.
   PubMed Web of Science ®Google Scholar
• Esquinas C, Ramon MA, Nuñez A, et al. Correlation between disease severity factors and EQ-5D utilities in chronic obstructive pulmonary disease. Qual Life Res. 2020;29(3):607–617.
   PubMed Web of Science ®Google Scholar
• Ramos-Goñi JM, Pinto-Prades JL, Oppe M, Cabasés JM, Serrano-Aguilar P, Rivero-Arias O. Valuation and modeling of EQ-5D-5L health states using a hybrid approach. Med Care. 2017;55(7):e51–e58.
   PubMed Web of Science ®Google Scholar
• Gisbert R, Brosa M. Healthcare Cost Database eSALUD. Oblikue Consulting, SL; 2019. Available from:http://www.oblikue.com/en/index.htm. Accessed April 1, 2019.
   Google Scholar
• Consejo General de Colegios Oficiales de Farmacéuticos. Bot PLUS 2.0. 2013. Available from: https://botplusweb.portalfarma.com. Accessed April 1, 2019.
   Google Scholar
• Del Estado. J [Spanish Royal Decree-Law 8/2010, May 20, whereby extraordinary measures are adopted to reduce the public deficit]. Boletín Oficial del Estado. 2010. Available from: https://www.boe.es/diario_boe/txt.php?id=BOE-A-2010-8228. Accessed August 17, 2017.
   Google Scholar
• Instituto Nacional de Estadística [INE]. [Annual Survey of Salary Structure 2016]. 2019. Available from: http://www.ine.es/. Accessed April 1, 2019.
   Google Scholar
• Soriano JB, Miravitlles M, Borderías L, et al. Geographical variations in the prevalence of COPD in Spain: relationship to smoking, death rates and other determining factors. Arch Bronconeumol. 2010;46(10):522–530.
   PubMed Web of Science ®Google Scholar
• Watz H, Tetzlaff K, Wouters EFM, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med. 2016;4(5):390–398.
   PubMed Web of Science ®Google Scholar
• Müllerová H, Meeraus WH, Galkin DV, Albers FC, Landis SH. Clinical burden of illness among patients with severe eosinophilic COPD. Int J Chron Obstruct Pulmon Dis. 2019;14:741–755.
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Calle M, Molina J, et al. Spanish COPD Guidelines (GesEPOC) 2021: updated Pharmacological treatment of stable COPD. Arch Bronconeumol. 2021; Mar 17:S0300-2896(21)00103-4. Online ahead of print.
   Web of Science ®Google Scholar
• Medina Gallardo J, Álvarez Guitiérrez F, Bordoy Sánchez M, et al. Análisis de los costes directos durante un año de pacientes con EPOC seguidos en una consulta neumológica extrahospitalaria. Neumosur. 2005;17(4):232–237.
   Google Scholar
• Trudo F, Kallenbach L, Vasey J, et al. Clinical and economic burden of eosinophilic COPD in a large retrospective US cohort. Int J Chron Obstruct Pulmon Dis. 2019;14:2625–2637.
   PubMed Web of Science ®Google Scholar
• López-Campos JL, Carrasco-Hernández L, Román Rodríguez L, Quintana-Gallego E, Carmona Bernal C, Alcázar Navarrete B. The clinical implications of triple therapy in fixed-dose combination in COPD: from the trial to the patient. Arch Bronconeumol. 2020;56(4):242–248.
   PubMed Web of Science ®Google Scholar
• Benson VS, Pascoe KC, Siddall J, Small M, Müllerová H. Exacerbation frequency and eosinophil counts among patients with COPD currently prescribed triple therapy. Int J COPD. 2019;14:2711–2723.
   Google Scholar
• Calverley PMA, Magnussen H, Miravitlles M, Wedzicha JA. Triple Therapy in COPD: what we know and what we don’t. COPD J Chronic Obstr Pulm Dis. 2017;14(6):648–662.
   PubMed Web of Science ®Google Scholar
• Soler-Cataluña JJ, Alcázar B, Miravitlles M. Clinical Control in COPD: a new therapeutic objective? Arch Bronconeumol. 2020;56(2):68–69.
   PubMed Web of Science ®Google Scholar
• Pérez de Llano L, Cosío BG, Miravitlles M, Plaza V; CHACOS study group. Accuracy of a New Algorithm to Identify Asthma-COPD Overlap (ACO) patients in a cohort of patients with Chronic Obstructive Airway Disease. Arch Bronconeumol. 2018;54(4):198–204.
   PubMed Web of Science ®Google Scholar
• Brusselle G, Pavord ID, Landis S, et al. Blood eosinophil levels as a biomarker in COPD. Respir Med. 2018;138:21–31.
   PubMed Web of Science ®Google Scholar
• Gonzalez‐Barcala F, San‐Jose M, Nieto‐Fontarigo J, et al. Blood eosinophils could be useful as a biomarker in chronic obstructive pulmonary disease exacerbations. Int J Clin Pract. 2019;73:12.
   Web of Science ®Google Scholar
• Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671–1680.
   PubMed Web of Science ®Google Scholar
• Instituto Nacional de Estadística [INE]. Encuesta Nacional de Salud 2011; 2019. Available from: www.ine.es.
   Google Scholar
• Miravitlles M, Huerta A, Valle M, et al. Clinical variables impacting on the estimation of utilities in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2015;10:367–377.
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Peña-Longobardo LM, Oliva-Moreno J, Hidalgo-Vega Á. Caregivers’ burden in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2015;10:347–356.
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Marín A, Huerta A, Carcedo D, Villacampa A, Puig-Junoy J. Estimation of the clinical and economic impact of an improvement in adherence based on the use of once-daily single-inhaler triple therapy in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2020;15:1643–1654.
   PubMed Web of Science ®Google Scholar
• Donovan T, Milan SJ, Wang R, Banchoff E, Bradley P, Crossingham I. Anti-IL-5 therapies for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2020;12:CD013432.
   PubMed Web of Science ®Google Scholar